| CEO Name | Marianne De Backer |
| Nationality | Belgium |
| Net Worth Estimation | $15 million |
Marianne De Backer's estimated net worth of around $15 million largely stems from her executive compensation, stock awards, and vested options as CEO of Vir Biotechnology, alongside previous high-level roles at Bayer and Johnson & Johnson. Public financial disclosures and equity grants issued during her tenure underpin this valuation.
Marianne De Backer, CEO of Vir Biotechnology, has an estimated net worth of $15,000,000, which is 7.14% above the minimum and 81.25% below the maximum CEO net worth in the biotechnology sector. Her net worth places her towards the lower end of the estimated CEO net worth range for this industry.
Business Category: Biotechnology
Minimum Net Worth (estimation): 10000000 USD
Maximum Net Worth (estimation): 80000000 USD
Marianne De Backer Performance in Vir Biotechnology
Marianne De Backer, CEO of Vir Biotechnology, demonstrates strategic leadership by driving innovative research and fostering partnerships to combat infectious diseases. Her decisive approach emphasizes accelerating product development and optimizing operational efficiency, significantly enhancing company performance. Under her leadership, Vir Biotechnology has strengthened its market position and advanced critical pipeline assets, markedly impacting company growth and shareholder value.
Latest News
Vir Biotechnology CEO Marianne De Backer Leads Company's Pivot to Cancer and Infectious Disease
Vir Biotechnology, under CEO Marianne De Backer, is shifting focus to cancer and infectious disease therapies after setbacks, launching new clinical trials and advancing its pipeline with dual-masked T-cell engagers. The company recently dosed its first patient in a Phase I trial for VIR-5525 and completed enrollment in a Phase III trial for chronic hepatitis delta.
Source: http://www.genengnews.com/topics/drug-discovery/vir-biotechnology-pivots-to-cancer-infectious-disease-after-commercial-and-clinical-setbacks/